Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 15/20 | 0.43 |
| ▸ | CNR2 | P34972 | 14/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7129686 | 0.91 | FABP4 (0.45) | CNR1CNR2FABP4 | |
| SCHEMBL7131196 | 0.84 | CNR1 (0.45) | CNR1CNR2ALDH1A1MAPTMEN1 | |
| SCHEMBL7122581 | 0.82 | PDE4B (0.53) | — | |
| SCHEMBL7122377 | 0.80 | FABP4 (0.51) | ALDH1A1MAPTFABP4MEN1KMT2A | |
| SCHEMBL5022790 | 0.77 | CNR1 (0.44) | CNR1CNR2ALDH1A1TSHRKMT2A | |
| SCHEMBL7066692 | 0.70 | FABP4 (0.60) | ALDH1A1FABP4MEN1KMT2A | |
| SCHEMBL5022751 | 0.69 | PRPS1 (0.43) | CNR1CNR2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL5516804 | 0.69 | TSHR (0.48) | CNR1CNR2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL6694479 | 0.68 | ALDH1A1 (0.41) | CNR1CNR2KDM4EALDH1A1KMT2A | |
| SCHEMBL5022760 | 0.67 | CNR1 (0.44) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004069831-A1 | TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-08-19 | — | — | WO | disclosed |